Inhibitors of Matrix Metalloproteinases

Wayne State University researchers and academic collaborators have prepared the first reported mechanism-based inhibitors for matrix metalloproteinases (MMPs). One of the novel compounds (SB-3CT) shows selectivity for the gelatinases (two members of the MMP family), which have been implicated in various pathological conditions including, but not limited, to the process of tumor metastasis and angiogenesis, cardiovascular diseases and neurological conditions. In vivo results from WSU and academic collaborators have shown promise in cancer therapy (in T-cell lymphoma and prostate cancer models), in stroke treatment, and in cardiovascular disease therapy.

Commercial Applications

• Therapeutic applications for cancer growth, tumor metastasis, angiogenesis, arthritis and connective tissue diseases, cardiovascular disease, inflammation and autoimmune diseases.

Competitive Advantage

• This type of inhibitor has a number of advantages over the known inhibitors for MMPs, as they are expected to show selectivity and potentially reduce toxicity to the host.

Patent Status

U.S. Patent No. 6,703,415 has been issued and other applications are on file; major foreign patent rights are available.